DEA schedule
Is Dovato a controlled substance?
Dovato contains dolutegravir and lamivudine. Federal schedule from the FDA NDC directory, checked against the DEA controlled substances list.
Source: FDA NDC Directory file dated 2026-10-22. Publisher page
No. Dovato (dolutegravir and lamivudine) is not a federally controlled substance. None of its FDA NDC listings carries a DEA schedule, and dolutegravir and lamivudine is not on the DEA controlled substances list.
Run it in Rivvi
Which 2027 plans near you dropped or restricted Dovato?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Schedule check
| Source | What it lists |
|---|---|
| FDA NDC directory | 1 prescription listings from 1 labelers, none with a DEA schedule |
| DEA controlled substances list | dolutegravir and lamivudine is not on the list |
Dovato NDC listings
| NDC | Product | Form | Strength | Labeler | DEA schedule |
|---|---|---|---|---|---|
| 49702-246 | Dovato | tablet, film coated | 50 mg/1; 300 mg/1 | ViiV Healthcare Company | None |
Questions
Is Dovato a controlled substance?
No. Dovato (dolutegravir and lamivudine) is not a federally controlled substance. None of its FDA NDC listings carries a DEA schedule, and dolutegravir and lamivudine is not on the DEA controlled substances list.
Is Dovato a narcotic?
No. Dovato (dolutegravir and lamivudine) is not on the DEA controlled substances list, so the DEA does not classify it as a narcotic. Its FDA established pharmacologic class is Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor and Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor and Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor.
Does this page cover state schedules?
No. This page reports the federal schedule only. Some states schedule drugs on their own; check your state board of pharmacy.
More on Dovato
- What is Dovato used for?FDA label uses
- Generic for DovatoFDA Orange Book
- Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitors listFDA drug class
- Human Immunodeficiency Virus Integrase Strand Transfer Inhibitors listFDA drug class
- Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitors listFDA drug class
- Dovato Medicare Part D coverageBy plan and state
- NDC 49702-246Dovato NDC record